Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease (vol 314, pg 142, 2015)

被引：2
|
作者：
Pandya, A.
Sy, S.
Cho, S.
Weinstein, M. C.
Gaziano, T. A.
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2015年 / 314卷 / 15期
关键词：
D O I：
10.1001/jama.2015.10251
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1647 / 1647
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
    Pandya, Ankur
    Sy, Stephen
    Cho, Sylvia
    Weinstein, Milton C.
    Gaziano, Thomas A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (02): : 142 - 150
  • [2] Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease
    Kohli-Lynch, Ciaran N.
    Lewsey, James
    Boyd, Kathleen A.
    French, Dustin D.
    Jordan, Neil
    Moran, Andrew E.
    Sattar, Naveed
    Preiss, David
    Briggs, Andrew H.
    [J]. CIRCULATION, 2022, 145 (17) : 1312 - 1323
  • [3] Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
    Shah, Aditya
    Sharma, Kamal
    Rawal, Shalin
    Sisodia, Rhea
    Bhatt, Parjanya
    Christian, Cleris
    Konat, Ashwati
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [4] CARDIOVASCULAR GENETIC RISK TESTING FOR TARGETING STATIN THERAPY IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A COST-EFFECTIVENESS ANALYSIS
    Jarmul, Jamie A.
    Pletcher, Mark J.
    Earnshaw, Stephanie
    Weinberger, Morris
    Jonas, Daniel
    Avery, Christy
    Lich, Kristen Hassmiller
    Wheeler, Stephanie
    Pignone, Michael
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S133 - S134
  • [5] Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease A Cost-Effectiveness Analysis
    Jarmul, Jamie
    Pletcher, Mark J.
    Lich, Kristen Hassmiller
    Wheeler, Stephanie B.
    Weinberger, Morris
    Avery, Christy L.
    Jonas, Daniel E.
    Earnshaw, Stephanie
    Pignone, Michael
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2018, 11 (04):
  • [6] Cost-Effectiveness of Polygenic Risk Scores to Guide Statin Therapy for Cardiovascular Disease Prevention
    Kiflen, Michel
    Le, Ann
    Mao, Shihong
    Lali, Ricky
    Narula, Sukrit
    Xie, Feng
    Pare, Guillaume
    [J]. CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2022, 15 (05): : 386 - 395
  • [7] COST-EFFECTIVENESS OF STATIN PRIORITISATION BASED ON ABSOLUTE RISK REDUCTION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
    Kohli-Lynch, C. N.
    Moran, A. E.
    Thanassoulis, G.
    Sniderman, A. D.
    Zhang, Y.
    Pencina, M.
    Pletcher, M. J.
    Vittinghoff, E.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A614 - A614
  • [8] Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis
    Boettiger, David C.
    Chattranukulchai, Pairoj
    Avihingsanon, Anchalee
    Chaiwarith, Romanee
    Khusuwan, Suwimon
    Law, Matthew G.
    Ross, Jeremy
    Kiertiburanakul, Sasisopin
    [J]. PLOS ONE, 2021, 16 (09):
  • [9] Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly
    Lin, Liang
    Teng, Monica
    Zhao, Ying Jiao
    Khoo, Ai Leng
    Seet, Raymond Chee Seong
    Yong, Quek Wei
    Yeo, Tiong Cheng
    Lim, Boon Peng
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2015, 29 (02) : 187 - 197
  • [10] Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly
    Liang Lin
    Monica Teng
    Ying Jiao Zhao
    Ai Leng Khoo
    Raymond Chee Seong Seet
    Quek Wei Yong
    Tiong Cheng Yeo
    Boon Peng Lim
    [J]. Cardiovascular Drugs and Therapy, 2015, 29 : 187 - 197
12345